MEI Pharma terminates Kyowa Kirin deal, regains full global rights to ME-401; urges vote for Infinity merger

Lite Strategy, Inc.

Mutually terminated License, Development and Commercialization Agreement with Kyowa Kirin for ME-401 effective July 14, 2023.
MEI regains full global rights to develop, manufacture and commercialize ME-401; Kyowa Kirin retains limited compassionate use until Nov 30, 2027.
Each party released the other from claims; MEI must deliver certain materials to Kyowa Kirin.
Press release reminds shareholders to vote FOR Infinity transaction at July 23 special meeting; ISS and Glass Lewis recommend FOR.

item 1.02 item 8.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Lite Strategy, Inc. terminated Original Agreement with Kyowa Kirin Co., Ltd. (effective 2023-07-14).

Action: termination
Agreement: license
Counterparty: Kyowa Kirin Co., Ltd.
Effective: 2023-07-14

Exact text from the filing

On July 14, 2023, the Company and Kyowa Kirin entered into a Termination Agreement (the “Termination Agreement”) to mutually terminate the Original Agreement, effective July 14, 2023

View on SEC.gov

197 material agreements filed in the last 30 days. Browse all material agreements →

Lite Strategy, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-23-189610

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.